Clinical trial
A Post-marketing Surveillance of Pariet Tab. 5 mg to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin, 100 mg or Less Daily, Administration in Korean Patients With a History of Gastric and Duodenal Ulcer
NCT05208268 is registered in ClinicalTrials.gov with Eisai Korea Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Post-marketing Surveillance of Pariet Tab. 5 mg to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin, 100 mg or Less Daily, Administration in Korean Patients With a History of Gastric and Duodenal Ulcer
- Lead sponsor
- Eisai Korea Inc.
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 23, 2020
- Completion date
- September 22, 2022
- Enrollment
- 676 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.